Rasio rega marang prakiraan pendapatan ikenaoncology.com (IMA)
ImageneBio Inc is currently optimizing expenses and seeking strategic allies. The company's capital is based on the development of targeted cancer therapies and licenses. The company's forward P/S reflects a fundamental margin of safety, with the value holding at 0.00. Business scaling relies on partnerships with pharma behemoths that assume the manufacturing costs.
IMA (ikenaoncology.com): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- rincian kapitalisasi pasar:
- indikator nilai buku ekuitas:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal ImageneBio Inc|IMA - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Ikena Oncology|IMA - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku IMA|IMA - Utang jangka dawa|Utang jangka cendhak perusahaan Ikena Oncology|Rasio cepet ikenaoncology.com
- rincian asil keuangan lan kelipatan valuasi:
IMA - Asil keuangan resik|Bathi sing dikarepake ImageneBio Inc|IMA - Kapitalisasi marang bathi|Prakiraan rega marang bathi Ikena Oncology|IMA - Koefisien bali modal nimbang wutah|Pangali EV/EBITDA IMA|IMA - Pendapatan operasional sadurunge ngurangi amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Ikena Oncology|IMA - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan ikenaoncology.com|IMA - Wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi kanggo taun ngarep ImageneBio Inc
- data total pendapatan lan volume dodolan:
Pambiji fundamental perusahaan:Ikena Oncology, Inc. IMA
Forward P/S reflects the market value of an asset relative to expected revenue, discounted at the WACC rate to assess the fair value of future cash flows. By analyzing the forward P/S metric, an investor determines the extent of the premium or discount, which is critical for ImageneBio Inc. (IMA), whose capitalization is currently based on the potential of its oncotherapeutic pipeline and preparations for clinical molecule releases.
Analisis pesaing
Multiplikator Forward P/S ARGX (argenx)|Rasio kapitalisasi marang dodolan sing dikarepake BioNTech Inc. (BNTX)|ABVX - Rasio rega marang prakiraan pendapatan|ADMA Corp (ADMA) - Multiplikator forward rega marang pendapatan|PTGX: Multiplikator Forward P/S|immunovant.com (IMVT) - Multiplikator Forward P/S|KNSA (Kiniksa) - Multiplikator Forward P/S|GRFS - Prakiraan rega marang pendapatan|Multiplikator Forward P/S ADPT|CLDX - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aurinia Pharmaceuticals AUPH|BCRX: Kapitalisasi marang prakiraan pendapatan|Vera Therapeutics - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Dianthus Therapeutics Inc|PHVS: Multiplikator Forward P/S|ABCL (AbCellera Corp) - Rasio rega marang prakiraan pendapatan|TRML (Tourmaline Bio, Inc.) - Multiplikator Forward P/S|precigen.com (PGEN) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Pharming Group (PHAR)|NKTR - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Upstream Bio Corp - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ZBIO|Immunome, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake gossamerbio.com GOSS|KalVista Pharmaceuticals, Inc. (KALV) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan SEPN|PVLA (Pieris Pharmaceuticals Inc) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Savara Pharma (SVRA)|Multiplikator Forward P/S RIGL|Rasio kapitalisasi marang dodolan sing dikarepake anaptysbio.com|Rasio rega marang prakiraan pendapatan Astria Therapeutics, Inc. ATXS|ENGN - Multiplikator forward rega marang pendapatan|RAPT Therapeutics, Inc. - Multiplikator Forward P/S|JBIO - Multiplikator Forward P/S|Aclaris Therapeutics (ACRS) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan KYTX (kyvernatx.com)|TLSA (Tiziana Life Sciences Ltd) - Multiplikator Forward P/S|CABA: Rega forward marang dodolan|Multiplikator Forward P/S VTYX|Multiplikator Forward P/S Theratechnologies, Inc (THTX)|Rasio rega marang prakiraan pendapatan Avalo Therapeutics, Inc AVTX|Rega forward marang dodolan ELDN|AGEN - Rasio rega marang prakiraan pendapatan|Climb Bio Inc. (CLYM) - Multiplikator forward rega marang pendapatan|ZURA: Multiplikator Forward P/S|aTyr Pharmaceuticals (ATYR) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan ADAG|STTK: Rega forward marang dodolan|Multiplikator Forward P/S EQ|Rasio kapitalisasi marang dodolan sing dikarepake connectbiopharm.com|Rasio rega marang prakiraan pendapatan Immunic IMUX|ATRA - Multiplikator forward rega marang pendapatan|IFRX - Rasio rega marang prakiraan pendapatan|x4pharma.com (XFOR) - Multiplikator forward rega marang pendapatan|ACET (adicetbio.com) - Multiplikator forward rega marang pendapatan|Celularity (CELU) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan INmune Bio Corp|Kapitalisasi marang prakiraan pendapatan BRNS (Barinthus Biotherapeutics Corp)|Multiplikator Forward P/S KZR|SABS - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Multiplikator Forward P/S AKTX (Akari Therapeutics Plc)|Rasio kapitalisasi marang dodolan sing dikarepake Enlivex Therapeutics Ltd (ENLV)|QTTB - Rasio rega marang prakiraan pendapatan|GeoVax Corp (GOVX) - Multiplikator forward rega marang pendapatan|EDSA: Multiplikator Forward P/S|ibioinc.com (IBIO) - Multiplikator Forward P/S|CARM (Carisma Therapeutics Inc) - Multiplikator Forward P/S|XTLB - Prakiraan rega marang pendapatan|Multiplikator Forward P/S BOLT|HCWB - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan Aptevo Therapeutics Inc. APVO|AIM: Kapitalisasi marang prakiraan pendapatan|Aditxt Corp - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep GRI Bio Inc|XRTX: Multiplikator Forward P/S|HIND (Vyome Therapeutics) - Rasio rega marang prakiraan pendapatan|REVB (Revelation Biosciences) - Multiplikator Forward P/S|indaptusrx.com (INDP) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Scinai Immunotherapeutics Ltd. (SCNI)|CALI - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Affimed N.V. - Multiplikator forward rega marang pendapatan|Rega forward marang dodolan ALLK|HOOKIPA - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake IGM Biosciences, Inc. IGMS|iTeos Therapeutics, Inc. (ITOS) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan OCEA|TCBP (TC BioPharm (Holdings) PLC) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Third Harmonic Bio Inc (THRD)
